Sagimet Biosciences

Develops oral FASN inhibitor drugs for metabolic and inflammatory diseases.

BiotechnologyPharmaceuticals sagimet.com ↗

Company facts

Founded
2006
Employees
24
Headquarters
United States
Type
Public
Listed
Nasdaq: SGMT